UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2012
File No. 000-54598
Stellar Biotechnologies Inc.
(Name of Registrant)
332 E. Scott Street, Port Hueneme, CA 93041
(Address of principal executive offices)
Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
FORM 20-F __X__
FORM 40-F ______
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ___
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.
Stellar Biotechnologies Inc.
(Registrant)
Dated: October 16, 2012 | By: /s/ "Darrell Brookstein" Darrell Brookstein Director |
Exhibits:
99.1
News Release dated October 15, 2012
99.2
News Release dated October 15, 2012 (2)
STELLAR ANNOUNCES $1 MILLION PRIVATE PLACEMENT
PORT HUENEME, CA (October 15, 2012) -- Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) announces a non-brokered private placement consisting of 4,000,000 units (the “Units”) at a purchase price of CDN $0.25 per Unit to raise gross proceeds of CDN $1,000,000 (the “Private Placement”). Each Unit will consist of one common share in the capital of the Company and one transferable share purchase warrant. Each warrant will entitle the holder to purchase one additional common share in the capital of the Company for a period of three years from the date of issuance, at a purchase price of CDN $0.40 per share. It is expected that current shareholders, including one insider, will collectively subscribe for the entire Private Placement, subject to the policies of the TSX Venture Exchange.
The Company may pay a finder’s fee to certain arm’s length parties in accordance with the policies of the TSX Venture Exchange. Such amounts will be paid either in cash or, at the discretion of the Company, the issuance of securities of the Company.
The securities issued will be subject to a hold period of four months and one day.
Proceeds of the Private Placement will be used for general working capital.
The Private Placement is subject to approval by the TSX Venture Exchange.
About Stellar Biotechnologies, Inc. (www.StellarBiotech.com)
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/
Contact:
Darrell Brookstein Executive VP,
Corporate Development & Finance
dbrookstein@stellarbiotech.com
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.
STELLAR BIOTECHNOLOGIES APPLIES TO AMEND WARRANTS
PORT HUENEME, CA (October 15, 2012) -- Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) announces that it will make an application to the TSX Venture Exchange to amend 6,153,000 share purchase warrants by extending the expiry date and reducing the exercise price.
The warrants form part of a non-brokered private placement (“Private Placement”) which closed on November 15, 2010 consisting of 6,213,000 units issued at a purchase price of CDN $0.60 per unit. Each unit consisted of one common share and one share purchase warrant, each warrant entitling the holder to purchase one additional common share on or before November 14, 2012, at an exercise price of CDN $0.90 per share if exercised on or before November 14, 2011 and CDN $1.15 per share if exercised from November 15, 2011 to November 14, 2012. An aggregate of 640,000 units in the Private Placement were subscribed for by insiders of the Company, including 60,000 units by a director of the Company. The warrants held by the director will not be amended. No warrants issued under the Private Placement have been exercised to date.
The warrants will be amended by extending the expiry date of the warrants by an additional twelve months, from November 14, 2012 to November 14, 2013 and reducing the exercise price of the warrants to CDN $0.71 per share.
The amendment is subject to approval by the warrant holders and the TSX Venture Exchange.
About Stellar Biotechnologies, Inc. (www.StellarBiotech.com)
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/
Contact:
Darrell Brookstein Executive VP,
Corporate Development & Finance
dbrookstein@stellarbiotech.com
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.